Peptides Similar to Tirzepatide

Peptides Related to Tirzepatide#

Tirzepatide belongs to the incretin-based therapeutic class, which leverages the physiological actions of gut-derived hormones to regulate glucose metabolism, appetite, and body weight. As a first-in-class dual GIP/GLP-1 receptor agonist, tirzepatide occupies a unique position among incretin therapies. The following comparison examines the most clinically relevant agents in this class, evaluating their mechanisms, clinical outcomes, dosing profiles, and safety data.

Semaglutide (Ozempic / Wegovy / Rybelsus)#

Semaglutide is a selective GLP-1 receptor agonist developed by Novo Nordisk, approved as Ozempic (2017) for type 2 diabetes and Wegovy (2021) for chronic weight management. An oral formulation (Rybelsus) is also approved for T2D. Semaglutide is a 31-amino-acid GLP-1 analog with an Aib substitution at position 8 for DPP-4 resistance and a C18 fatty diacid at Lys26 for albumin binding, conferring a half-life of approximately 7 days and once-weekly dosing.

Mechanism comparison: Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. The dual mechanism of tirzepatide is hypothesized to produce complementary metabolic effects: GLP-1R activation enhances glucose-dependent insulin secretion, suppresses glucagon, and reduces appetite, while GIPR activation may potentiate insulin secretion, improve lipid metabolism, modulate fat distribution, and contribute to central appetite regulation through distinct neural pathways.

Clinical efficacy -- head-to-head data: The SURPASS-2 trial directly compared tirzepatide (5, 10, and 15 mg weekly) to semaglutide 1 mg weekly in 1,879 adults with type 2 diabetes over 40 weeks. Key findings:

• HbA1c reduction: tirzepatide 15 mg achieved -2.46% vs. semaglutide 1 mg at -1.86% (treatment difference -0.60%, P<0.001).
• Body weight reduction: tirzepatide 15 mg achieved -12.4 kg vs. semaglutide 1 mg at -6.2 kg (treatment difference -6.2 kg, P<0.001).
• All three tirzepatide doses were statistically superior to semaglutide 1 mg for both HbA1c and weight reduction.

In the obesity/weight management setting, the SURMOUNT trials demonstrated weight loss of 15.0-22.5% with tirzepatide, while the STEP trials with semaglutide 2.4 mg showed approximately 14.9-16.0% weight loss. Although these are cross-trial comparisons (not head-to-head in obesity), the magnitude favors tirzepatide. A direct comparison trial (SURMOUNT-5) was conducted and reported tirzepatide superiority for weight loss versus semaglutide in an obesity population.

Dosing and convenience: Both agents are dosed once weekly via subcutaneous injection. Semaglutide offers the additional option of a daily oral tablet (Rybelsus 7 or 14 mg) for T2D, though the oral formulation requires fasting conditions and achieves lower bioavailability. Semaglutide dose escalation is simpler (0.25 mg to 0.5 mg to 1.0 mg for Ozempic; up to 2.4 mg for Wegovy), while tirzepatide requires more steps (2.5 to 5, 7.5, 10, 12.5, and 15 mg).

Side effect profile: Both agents share gastrointestinal adverse effects as the most common class effect (nausea, diarrhea, vomiting, constipation). In SURPASS-2, the incidence of nausea was comparable between tirzepatide 15 mg (~23%) and semaglutide 1 mg (~22%). Overall GI tolerability was similar between agents. Both carry the same boxed warning regarding thyroid C-cell tumors based on rodent data.

Cardiovascular outcomes: Semaglutide has a more extensive cardiovascular evidence base, with SUSTAIN-6 demonstrating a reduction in major adverse cardiovascular events (MACE) in T2D, and SELECT demonstrating cardiovascular benefit in obesity without diabetes. Tirzepatide cardiovascular outcomes data are still maturing, with the SURPASS-CVOT trial ongoing.

Retatrutide (LY3437943)#

Retatrutide is an investigational triple incretin receptor agonist developed by Eli Lilly that activates GIP, GLP-1, and glucagon receptors simultaneously. It is currently in phase 3 clinical development for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).

Mechanism comparison: While tirzepatide activates GIP and GLP-1 receptors, retatrutide adds glucagon receptor (GCGR) activation as a third mechanism. Glucagon receptor agonism is hypothesized to increase hepatic energy expenditure, promote lipid oxidation, and enhance thermogenesis, potentially contributing to greater fat mass reduction. However, glucagon also stimulates hepatic glucose output, which must be counterbalanced by the insulin-stimulatory effects of GIP and GLP-1 receptor activation.

Clinical efficacy: In the phase 2 trial published in the New England Journal of Medicine (2023), retatrutide achieved remarkable weight reductions in adults with obesity:

• At 48 weeks, the highest dose (12 mg) achieved a mean weight reduction of approximately 24.2%, exceeding the 22.5% seen with tirzepatide 15 mg in SURMOUNT-1.
• HbA1c reductions in a T2D cohort were also substantial, comparable to or exceeding tirzepatide.
• Hepatic fat reductions were notable, with over 80% of participants with MASH achieving hepatic steatosis resolution, suggesting particular benefit in fatty liver disease.

These results are promising, but phase 2 data should be interpreted cautiously pending confirmation in larger phase 3 trials.

Safety considerations: Retatrutide shares the GI side effect profile of other incretin agonists but may carry additional considerations related to glucagon receptor activation, including theoretical concerns about hepatic glucose output (mitigated by GIP/GLP-1 co-agonism), potential effects on amino acid metabolism, and possible impacts on lean mass. The long-term safety profile is not yet established.

Regulatory status: Retatrutide is not yet FDA-approved and remains investigational as of 2026. Phase 3 trials (TRIUMPH program) are ongoing. By contrast, tirzepatide has been FDA-approved since 2022 (Mounjaro) and 2023 (Zepbound), with extensive phase 3 data and growing real-world evidence.

Liraglutide (Victoza / Saxenda)#

Liraglutide is a selective GLP-1 receptor agonist developed by Novo Nordisk, approved as Victoza (2010) for type 2 diabetes and Saxenda (2014) for chronic weight management. It is a 30-amino-acid GLP-1 analog with a C16 fatty acid at Lys26, providing a half-life of approximately 13 hours and requiring once-daily injection.

Mechanism comparison: Like semaglutide, liraglutide acts exclusively on GLP-1R. Compared to tirzepatide's dual GIP/GLP-1 mechanism, liraglutide's single receptor target results in a narrower pharmacological profile and lower clinical efficacy for both glycemic control and weight loss.

Clinical efficacy: In the LEADER trial (T2D), liraglutide reduced HbA1c by approximately 1.16% from baseline. In the SCALE Obesity trial, liraglutide 3.0 mg daily achieved approximately 5.4-8.0% weight loss over 56 weeks. These results are substantially lower than tirzepatide's performance: SURPASS trials showed HbA1c reductions of 1.87-2.58%, and SURMOUNT-1 demonstrated 15.0-22.5% weight loss.

Dosing and convenience: The most significant practical difference is dosing frequency. Liraglutide requires daily subcutaneous injection (up to 1.8 mg for Victoza; up to 3.0 mg for Saxenda), while tirzepatide is dosed once weekly. This weekly versus daily dosing difference is a meaningful factor for patient adherence and quality of life, with multiple studies demonstrating patient preference for weekly over daily injections.

Safety and long-term data: Liraglutide has the longest market track record among the comparators discussed here, with over 12 years of clinical use and extensive post-marketing surveillance data. The LEADER trial demonstrated a cardiovascular benefit (reduction in MACE), and liraglutide has an established pediatric indication for obesity (Saxenda in adolescents aged 12+). The GI side effect profile (nausea, diarrhea, vomiting) is qualitatively similar to tirzepatide but may be somewhat less pronounced due to the lower weight and glycemic potency.

Combination and Synergy Considerations#

The incretin-based agents discussed above are not typically combined with each other in clinical practice, as their overlapping mechanisms would present additive GI side effect risk and hypoglycemia potential without established additive benefit. However, all of these agents may be combined with other diabetes medications:

• Metformin: Standard first-line T2D therapy; frequently used alongside incretin agonists.
• SGLT2 inhibitors: Complementary mechanism (renal glucose excretion); commonly combined.
• Insulin: May be used with dose adjustment; combination requires monitoring for hypoglycemia.

Evidence Gaps#

• No head-to-head trial of tirzepatide versus retatrutide has been conducted.
• Long-term comparative cardiovascular outcomes between tirzepatide and semaglutide are pending.
• Comparative effects on lean body mass preservation across the agents are not well characterized.
• Head-to-head comparisons in specific populations (e.g., heart failure with preserved ejection fraction, MASH, obstructive sleep apnea) are limited.
• Long-term weight regain patterns after discontinuation of each agent require further study, as available data suggest substantial weight regain after stopping therapy.

Related Reading#

• Tirzepatide overview and research guide
• Tirzepatide research evidence
• Tirzepatide dosing protocols